| Ytd | 3.74% | |
| 1y | 120.45% |
| Open | 3.90 | Prev Close | 3.90 | Low | 3.81 | High | 3.93 | Mkt Cap | 296.68M |
| Vol | 302.89K | Avg Vol | 849.85K | EPS | -0.58 | P/E | N/A | Forward P/E | -1.56 |
| Beta | 0.64 | Short Ratio | 1.22 | Inst. Own | 34.25% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 3.69 | 200-d Avg | 3.58 | 1yr Est | 12.40 |
SABS News
Barclays analyst Eliana Merle initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Over
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and rai
Top Wall Street analysts changed their outlook on top names. See all rating changes on our analyst r
Leerink Partners analyst Thomas Smith maintains SAB Biotherapeutics (NASDAQ:SABS) with a Outperfo
HC Wainwright & Co. analyst Emily Bodnar reiterates SAB Biotherapeutics (NASDAQ:SABS) with a
Citigroup analyst Samantha Semenkow initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with
Wall Street analysts changed outlook on top names. See full ratings page for upgrades, downgrades, a
Jefferies analyst Roger Song initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy r
HC Wainwright & Co. analyst Emily Bodnar maintains SAB Biotherapeutics (NASDAQ:SABS) with a B
SAB Biotherapeutics (NASDAQ:SABS) reported quarterly losses of $(0.35) per share which missed the an
Rodman & Renshaw analyst Seema Sheoran reiterates SAB Biotherapeutics (NASDAQ:SABS) with a Bu
The executed agreement is valued at approximately $50 million, of which $36 million is contingent on
SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fu
SAB Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing a ful
HC Wainwright & Co. analyst Emily Bodnar maintains SAB Biotherapeutics (NASDAQ:SABS) with a B
T1D key opinion leader, Michael J. Haller, MD, provided a recorded webinar reviewing the SAB-142 Pha
UBS analyst Michael Yee initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Buy rating
Guggenheim analyst Yatin Suneja initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Bu
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and mai
Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dos
SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing huma
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and mai
SAb Biotherapeutics, Inc. (NASDAQ:SABS), a clinical-stage biopharmaceutical company developing human
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and mai
Leerink Partners initiates coverage on SAB Biotherapeutics (NASDAQ:SABS) with a Outperform rating
MIAMI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB BIO
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and low
HC Wainwright & Co. analyst Emily Bodnar maintains SAB Biotherapeutics (NASDAQ:SABS) with a B
Participation from strategic investor Sanofi, along with new investors RA Capital Management, Commod
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and mai
HC Wainwright & Co. analyst Emily Bodnar assumes SAB Biotherapeutics (NASDAQ:SABS) with a Buy
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and low
HC Wainwright & Co. analyst Edward White reiterates SAB Biotherapeutics (NASDAQ:SABS) with a
Chardan Capital analyst Keay Nakae maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and mai
HC Wainwright & Co. analyst Edward White reiterates SAB Biotherapeutics (NASDAQ:SABS) with a